All In Biotech

Drug Trial Radar · NCT07177469

UBT251 Injection Phase II Study (Overweight or Obesity)

A Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

205

Actual

Start

Mar 14, 2025

Primary completion

Oct 22, 2025

Study completion Nov 19, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients

Conditions

  • Obesity &Amp; Overweight

Interventions

  • UBT251 Injection 2.0 mg and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

  • UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

  • UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

  • UBT251 Injection 6.0 mg and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Body WeightTime frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.